Medpace Holdings Inc vs Monolithic Power Systems Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Monolithic Power Systems Inc trades at $1,386.35 (market cap $67.32B). The key difference: Monolithic Power Systems Inc is far larger — about 4× Medpace Holdings Inc's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Monolithic Power Systems Inc for 25 Days on average.
| MEDP | MPWR | |
|---|---|---|
Market Cap | $16.82B | $67.32B |
Volume | 223,093 | 826,960 |
Sector | Health | Technology |
52-Week High | $630.19 | $1.69K |
52-Week Low | $393.42 | $856.96 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | $16.44B | $65.92B |
Dividend Yield | — | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
MPWR trades at $1,425.98, down 3.24% today but maintains strong technical momentum with bullish moving averages and key support at $1,417. The company demonstrates robust fundamentals with 24.5% net margins and consistent earnings beats, while expanding manufacturing capacity through the GlobalFoundries partnership announced September 9, 2026. Analyst sentiment remains overwhelmingly positive with 88% buy ratings and a $1,830 consensus price target representing 28% upside potential.
MPWR presents compelling growth exposure to AI infrastructure demand but carries premium valuation risks. The stock's 83.6 P/E ratio requires sustained high growth execution, while insider selling and competitive pressures warrant monitoring. Current technical positioning near pivot point resistance at $1,427 suggests near-term consolidation before potential breakout toward analyst targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →